Statins, fatigue and muscle pain: what do the trials say, and what should you do?

Yes, but far less often than people think: in large double-blind trials, the statin accounts for only a small share of the muscle pain reported by participants.

In 2022, the CTT (Cholesterol Treatment Trialists) collaboration analysed individual data from 19 trials comparing a statin with a placebo, covering 123,940 participants followed for 4.3 years (weighted median duration). Muscle pain or weakness was reported by 27.1% of participants on a statin and by 26.6% of those on placebo, a rate ratio of 1.03¹.

The excess is concentrated in the first year, when the statin increases reports by 7%, or 11 extra events per 1,000 person-years. The authors conclude that around one report in 15 among people on a statin was actually due to the drug. After the first year, the difference disappears. The most intensive regimens (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) show a slightly greater excess than moderate doses (1.08 versus 1.03)¹.

This analysis does not deny the effect; it quantifies it. According to its authors, more than 90% of the muscle symptoms reported on statins would have occurred without them, and the observed rise in CK remains minimal¹.

The nocebo effect refers to real symptoms triggered by the expectation of a side effect rather than by the substance itself. Two British trials measured it in people who had stopped, or wanted to stop, their statin because of pain.

In SAMSON, 60 patients received 12 monthly bottles in random order: four contained 20 mg atorvastatin, four a placebo and four were empty. They rated their symptoms on a scale of 0 to 100. The average score was 8.0 in months without tablets, 15.4 on placebo and 16.3 on the statin: 90% of the discomfort felt on the statin also appeared on placebo. Six months later, half of the participants had restarted their statin².

StatinWISE applied the same principle in 50 general practices. The 200 participants alternated six two-month periods on 20 mg atorvastatin or placebo, without knowing which. Among the 151 participants analysed, muscle symptom scores did not differ (mean difference −0.11 points out of 10; 95% CI −0.36 to 0.14). Withdrawals due to intolerable pain affected 9% of participants during a statin period and 7% during a placebo period. Two thirds of those who completed the trial said they would restart their treatment³.

The ASCOT-LLA trial had already shown the phenomenon on a large scale. As long as neither patients nor doctors knew who was receiving atorvastatin, muscle complaints were as frequent on the statin as on placebo (2.03% versus 2.00% a year). In the open-label phase that followed, when everyone knew their treatment, they became 41% more frequent among statin users (hazard ratio 1.41)⁴.

One randomised trial suggests a slight effect of statins on energy and fatigue with exertion, more marked in women, but the data are far thinner than for muscle pain.

In the UCSD Statin Study, 1,016 adults without cardiovascular disease or diabetes took 20 mg simvastatin, 40 mg pravastatin or a placebo for 6 months. They rated changes in their energy and fatigue with exertion on a combined scale from −4 to +4. The score fell by 0.21 points on statins, versus 0.06 on placebo. The difference was clearer in women (−0.39 on statins versus −0.08 on placebo), and even more so in those taking simvastatin (−0.47)⁵.

The measured effect is small and rests on two self-rated questions. Conversely, in the blinded phase of ASCOT-LLA, sleep disturbances were reported less often on atorvastatin than on placebo (1.00% versus 1.46% a year)⁴. Fatigue also has many other possible causes, such as lack of sleep, anaemia or hypothyroidism. The European panel in fact lists untreated or poorly treated hypothyroidism among the risk factors for muscle symptoms on statins⁶.

Intense muscle pain, unusual weakness or dark urine call for prompt medical attention: these signs can indicate serious muscle damage, which is rare but real⁶.

Typical pain usually affects both sides of the body and the large muscle groups (thighs, buttocks, calves, back). It most often appears within 4 to 6 weeks of starting treatment, but can occur after years, for example after a dose increase or the addition of an interacting medicine⁶. The doctor then measures creatine kinase (CK), an enzyme released by damaged muscle. The European Atherosclerosis Society panel distinguishes several situations⁶ :

• Normal CK: this is called myalgia. The link with the statin remains uncertain, since blinded trials show no clear excess of these symptoms.
• CK between 4 and 10 times the upper limit: depending on cardiovascular risk, the doctor stops the statin or continues it while monitoring CK.
• CK above 10 times the limit: this is called myopathy, which affects between 1 in 1,000 and 1 in 10,000 people a year depending on the statin, the dose and risk factors. If there is no other cause, the statin is stopped.
• CK above 40 times the limit, with kidney damage or myoglobin in the urine: this is called rhabdomyolysis, estimated at around 1 case per 100,000 people a year.

The panel does not recommend routine CK testing in people without symptoms. Several factors increase the risk: age over 80, untreated hypothyroidism, kidney or liver disease, a high dose, or combination with certain medicines (gemfibrozil, some macrolide antibiotics, azole antifungals, ciclosporin)⁶. According to the American Heart Association scientific statement, the risk of serious muscle damage, including rhabdomyolysis, remains below 0.1%⁷.

Talk to your doctor rather than stopping on your own: many people affected can continue lipid-lowering treatment by changing the dose or the molecule.

The European panel proposes a structured approach. The doctor checks that the symptoms are typical, observes whether they subside when the statin is stopped and return when it is restarted, then generally tries at least three statins in succession. The doctor may keep the best-tolerated dose and combine it with a lipid-lowering drug from another class to reach the LDL cholesterol target⁶.

Individual trials such as SAMSON and StatinWISE open up another route. Alternating blinded periods of statin and placebo allows each person to measure what is really down to their treatment. In StatinWISE, two thirds of participants who completed the trial restarted their statin³.

Do not stop your statin on your own initiative: the decision is made with your doctor, who weighs the symptoms against cardiovascular risk.

The American Heart Association statement reports that in the United States, around 10% of patients stop their statin because of subjective complaints, most often muscular and without a rise in CK. Yet in randomised trials, the difference in how often these symptoms occur on statin versus placebo remains below 1%⁷. The authors of the CTT meta-analysis conclude that these small muscle risks are far smaller than the known cardiovascular benefits of treatment¹. Stopping on your own means risking the loss of this benefit without knowing whether the statin was to blame.

It is also best not to rely on a supplement to silence pain without discussing it. Coenzyme Q10 and vitamin D are often suggested, but the European panel recommends neither to treat or prevent these symptoms, for lack of consistent evidence⁶. Finally, severe pain, weakness or dark urine should never be endured in silence.